An interrupted time series study of electronic health record clinical decision support for providers caring for patients with atrial fibrillation at increased stroke risk.


Journal

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
ISSN: 1535-2900
Titre abrégé: Am J Health Syst Pharm
Pays: England
ID NLM: 9503023

Informations de publication

Date de publication:
05 Dec 2023
Historique:
medline: 6 12 2023
pubmed: 12 9 2023
entrez: 11 9 2023
Statut: ppublish

Résumé

To measure the effect of clinical decision support (CDS) on anticoagulation rates in patients with atrial fibrillation (AFib) or atrial flutter (AFlut) at high stroke risk and receiving care in outpatient settings, and to assess provider response to CDS. This observational, quasi-experimental, interrupted time series study utilized electronic health record data at a large integrated delivery network in Texas from April to November 2020. CDS consisted of an electronic Best Practice Advisory (BPA)/alert (Epic Systems Corporation, Verona, WI) with links to 2 AFib order sets displayed to providers in outpatient settings caring for non-anticoagulated patients with AFib and elevated CHA2DS2VASc scores. Weekly outpatient anticoagulation rates were assessed in patients with high stroke risk before and after implementation of CDS. Alert actions and acknowledgment reasons were evaluated descriptively. Mean (SD) weekly counts of eligible patients were 8,917 (566) before and 8,881 (811) after implementation. Weekly anticoagulation rates increased during the pre-BPA study period (β1 = 0.07%; SE, 0.02%; P = 0.0062); however, there were no significant changes in the level (β2 = 0.60%; SE, 0.42%; P = 0.1651) or trend (β3 = -0.01%; SE, 0.05%; P = 0.8256) of anticoagulation rates associated with CDS implementation. In encounters with the BPA/alert displayed (n = 17,654), acknowledgment reasons were provided in 4,473 (25.3%) of the encounters, with prescribers most commonly citing bleeding risk (n = 1,327, 7.5%) and fall risk (n = 855, 4.8%). There was a significant trend of increasing anticoagulation rates during the pre-BPA period, with no significant change in trend during the post-BPA period relative to the pre-BPA period.

Identifiants

pubmed: 37696764
pii: 7269159
doi: 10.1093/ajhp/zxad188
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1830-1839

Informations de copyright

© American Society of Health-System Pharmacists 2023. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Andrew J Osterland (AJ)

Baylor Scott & White Health, Temple, TX, USA.

Marie Yasuda (M)

Baylor Scott & White Health, Temple, TX, USA.

Robert J Widmer (RJ)

Baylor Scott & White Health, Temple, TX, USA.

Anthony C Colavecchia (AC)

Pfizer Inc., New York, NY, USA.

Tyler Gums (T)

Pfizer Inc., New York, NY, USA.

Birol Emir (B)

Pfizer Inc., New York, NY, USA.

Kim Nolen (K)

Pfizer Inc., New York, NY, USA.

Elizabeth MacLean (E)

Pfizer Inc., New York, NY, USA.

Paul J Godley (PJ)

Baylor Scott & White Health, Temple, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH